Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
Type:
Application
Filed:
July 10, 2019
Publication date:
March 10, 2022
Applicants:
Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
Inventors:
Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Xiaodi Deng, Lin Hui Su, Ginger Rakestraw, Jason R. Pinckney, David A. Critton, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova, Michael Quigley, Hadia Lemar, Akbar Nayeem
Abstract: This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
Type:
Application
Filed:
July 2, 2021
Publication date:
February 10, 2022
Applicant:
Five Prime Therapeutics, Inc.
Inventors:
Helen L. Collins, James Hnatyszyn, Hong Xiang, Xiang Zhang
Abstract: The present invention provides antibodies that bind FGFR2IIIb, wherein the antibodies are afucosylated. The present invention provides compositions comprising antibodies that bind FGFR2IIIb, wherein at least 95% of the antibodies in the composition are afucosylated. In some embodiments, methods of treating cancer comprising administering afucosylated anti-FGFR2IIIb antibodies are provided.
Type:
Grant
Filed:
November 6, 2018
Date of Patent:
February 1, 2022
Assignee:
Five Prime Therapeutics, Inc.
Inventors:
Thomas Harding, Kristen Pierce, Namrata Patil, Thomas Brennan, Julie Hambleton
Abstract: This disclosure relates to a formulation of an anti-fibroblast growth factor receptor 2 (FGFR2) antibody that, in some embodiments, is capable of being stored as a liquid, for example in a ready-to-use form, and that, in some embodiments, may be administered intravenously such as by intravenous (IV) infusion.
Abstract: Antibodies that bind CSF1R are provided. Antibody heavy chains and light chains that are capable of forming antibodies that bind CSF1R are also provided. Polynucleotides encoding antibodies to CSF1R are provided. Polynucleotides encoding antibody heavy chains and lights chains are also provided. Methods of treatment using antibodies to CSF1R are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis, bone loss, and multiple sclerosis.
Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.
Type:
Application
Filed:
February 24, 2021
Publication date:
October 14, 2021
Applicant:
Five Prime Therapeutics, Inc.
Inventors:
Julie Hambleton, Emma Masteller, James Zanghi, Robert Sikorski, Hong Xiang
Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.
Type:
Application
Filed:
February 11, 2021
Publication date:
September 9, 2021
Applicant:
Five Prime Therapeutics, Inc.
Inventors:
Brian Wong, Emma Masteller, Justin Wong, Haishan Lin
Abstract: This application relates to CD80 (B7-1) extracellular domain (ECD) polypeptides and CD80-ECD fusion molecules and their use in treatment of cancer, both alone and in combination with other therapeutic agents, such as immune stimulating agents such as PD-1/PD-L1 inhibitors.
Type:
Grant
Filed:
March 15, 2019
Date of Patent:
August 24, 2021
Assignee:
Five Prime Therapeutics, Inc.
Inventors:
Thomas Brennan, David Bellovin, David Busha, Barbara Sennino
Abstract: This application relates to uses of antibodies against fibroblast growth factor receptor 2 (FGFR2), including antibodies against the FGFR2 isoform FGFR2-IIIb (also known as FGFR2b), in treatment of certain cancers in combinations with mFOLFOX6 chemotherapy.
Type:
Grant
Filed:
May 15, 2018
Date of Patent:
August 17, 2021
Assignee:
Five Prime Therapeutics, Inc.
Inventors:
Helen L. Collins, James Hnatyszyn, Hong Xiang, Xiang Zhang
Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis and associated conditions, methods of treating systemic lupus erythematosus and associated conditions, and methods of treating multiple sclerosis.
Type:
Grant
Filed:
May 11, 2016
Date of Patent:
April 20, 2021
Assignee:
Five Prime Therapeutics, Inc.
Inventors:
Brian Wong, Emma Masteller, Justin Wong, Haishan Lin
Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.
Type:
Application
Filed:
September 21, 2020
Publication date:
April 15, 2021
Applicant:
Five Prime Therapeutics, Inc.
Inventors:
Brian Wong, Emma Masteller, Kris Reedquist
Abstract: Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating rheumatoid arthritis.
Type:
Grant
Filed:
June 18, 2015
Date of Patent:
April 13, 2021
Assignee:
Five Prime Therapeutics, Inc.
Inventors:
Julie Hambleton, Emma Masteller, James Zanghi, Robert Sikorski, Hong Xiang
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
Type:
Application
Filed:
March 19, 2019
Publication date:
January 21, 2021
Applicants:
Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
Inventors:
Robert J. Johnston, Arvind Rajpal, Paul O. Sheppard, Luis Borges, Andrew Rankin, Keith Sadoon Bahjat, Alan J. Korman, Xiaodi Deng, Lin Hui Su, Ginger Rakestraw, Jason R. Pinckney, David A. Critton, Guodong Chen, Richard Y. Huang, Ekaterina G. Deyanova
Abstract: Methods of treating pigmented villonodular synovitis (PVNS) with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.
Type:
Application
Filed:
June 25, 2020
Publication date:
January 14, 2021
Applicant:
Five Prime Therapeutics, Inc.
Inventors:
Robert Sikorski, Julie Hambleton, Nilacantan Sankar
Abstract: The present invention relates to methods of treating pancreatic cancer with particular dosage regimes of antibodies that bind colony stimulating factor 1 receptor (CSF1R) (e.g. cabiralizumab) in combination with antibodies that bind programmed cell death 1 (PD-1) (e.g. nivolumab).
Type:
Application
Filed:
September 12, 2018
Publication date:
January 14, 2021
Applicants:
Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
Inventors:
Katherine E. Lewis, Serena Kimi Perna, Michael Carleton, Ke Xu, Penny Phillips, Dimple Pandya, Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Janine Powers, Ernestine Lee
Abstract: Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.
Type:
Grant
Filed:
January 24, 2019
Date of Patent:
November 3, 2020
Assignee:
Five Prime Therapeutics, Inc.
Inventors:
Brian Wong, Emma Masteller, Kris Reedquist
Abstract: Methods of treating muscle wasting and other disorders with NOPE extracellular domain (ECD) polypeptides and NOPE ECD fusion molecules are provided.
Type:
Grant
Filed:
April 24, 2017
Date of Patent:
October 13, 2020
Assignees:
Five Prime Therapeutics, Inc., Glaxosmithkline Intellectual Property Development Limited
Inventors:
Aaron Curtis Hinken, Amy W. Hsu, Janine Powers, Warren James Rocque, Alan James Russell
Abstract: Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with PD-1/PD-L1 inhibitors are provided.
Type:
Application
Filed:
March 4, 2020
Publication date:
September 24, 2020
Applicants:
Five Prime Therapeutics, Inc., Bristol-Myers Squibb Company
Inventors:
Brian Wong, Julie Hambleton, Robert Sikorski, Emma Masteller, Kevin Hestir, David Bellovin, Katherine E. Lewis
Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
Type:
Application
Filed:
March 10, 2020
Publication date:
August 13, 2020
Applicant:
Five Prime Therapeutics, Inc.
Inventors:
Charles KAPLAN, Derrick HOUSER, Luis BORGES, Gloria BRATTICH, David BELLOVIN, Felicia KEMP, Majid GHODDUSI, Nels P. NIELSON, Kathy MILLER, Maike SCHMIDT
Abstract: Methods of treating pigmented villonodular synovitis (PVNS) with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided.
Type:
Grant
Filed:
June 22, 2018
Date of Patent:
August 4, 2020
Assignee:
Five Prime Therapeutics, Inc.
Inventors:
Robert Sikorski, Julie Hambleton, Nilacantan Sankar